From Hype to Human Trials: What 9 Longevity Startups Are Building in 2026
Nine companies, seven mechanisms - longevity biotech is finally doing the hard science
For years, the longevity industry attracted as much skepticism as it did investment. The promises were big: reverse aging, live to 150, reprogram your cells, but the clinical evidence was thin. In 2026, that dynamic is beginning to change, not because aging has been “cured,” but because the most serious companies in the field have done something strategically important: they have stopped fighting to make aging a disease and started building programs around specific diseases that aging makes worse.
I will discuss here nine startups doing interesting work in this difficult field of longevity science.
Reprogramming Leads the Field
The most consequential idea in longevity biotech right now is partial epigenetic reprogramming, which means using Yamanaka transcription factors (OCT4, SOX2, KLF4, and sometimes c-MYC) to reset a cell’s epigenetic state without altering its DNA sequence.
The goal is not to turn a differentiated cell into a stem cell, but to walk it back partway, erasing the molecular markers of cellular aging while preserving its identity and function.
Life Biosciences has advanced this idea furthest in clinical terms. In January 2026, the company received FDA clearance of an IND for ER-100, its OSK gene therapy delivered via adeno-associated virus to retinal cells in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). NAION is the most common acute optic neuropathy in adults over 50, and there are currently no approved treatments, making it an ideal first indication. This is the first FDA-cleared human trial of cellular reprogramming, and while it is still an early safety study, it represents a landmark regulatory and scientific step.
Altos Labs, backed by some of the largest funding rounds in biotech history, is pursuing a broader reprogramming vision with an important computational layer. Its teams are developing models to understand and limit “cellular drift,” the gradual loss of regulatory precision in aging cells alongside the reprogramming biology itself. The hypothesis is that reprogramming without accounting for cell-state stability is incomplete, and that durable rejuvenation will require both the reset signal and computational frameworks to validate that the reset holds.
YouthBio Therapeutics is taking reprogramming directly to the brain with YB002, a gene therapy designed to partially reprogram neurons and glial cells to reverse epigenetic changes associated with Alzheimer’s disease. This is a high-risk, high-reward approach given the complexity of CNS delivery and the failure rate of Alzheimer’s trials.
But the logic is sound: Alzheimer’s pathology develops on a background of epigenetically aged brain cells, and reversing that background state before or alongside disease-specific interventions may improve outcomes in ways that current disease-modifying therapies cannot.
Turn Biotechnologies adds a delivery innovation to the reprogramming story with its ERA and eTurna platforms, which combine epigenetic reprogramming with mRNA-based delivery technologies. The mRNA approach is appealing because it is transient, reducing the safety concerns around sustained transgene expression. Turn has applied this platform to skin rejuvenation and age-related skin diseases, which are easier to access topically and provide the company with a distinct dermatologic clinical pathway distinct from the ocular and neurological programs above.
AI Is Part of the Solution, Not a Marketing Term
Several companies in this cohort are doing something more than applying standard bioinformatics. They are building proprietary computational platforms in which AI serves as the primary hypothesis generator.
Junevity is one of the most conceptually interesting examples. Its RESET platform integrates large-scale human molecular datasets to identify transcription factors that are causally driving aging biology, then targets those factors with siRNA therapies.
Current programs are focused on type 2 diabetes, obesity, and frailty; conditions where age-related transcriptional dysregulation is well-documented but poorly targeted by existing drugs. The company is effectively treating these diseases as transcriptional problems, an approach that may open new target classes that conventional pharmacology has not yet explored.
Gero is applying a physics-inspired framework to the biology of aging, mining large human datasets to model the dynamics of physiological dysregulation over time. The platform has produced drug targets validated through a partnership with other companies. For physicians, Gero’s approach is interesting because it is grounded in systems-level physiology rather than individual molecular targets, which may be better suited to complex multisystem diseases.
Rubedo Life Sciences is pairing its ALEMBIC AI platform with a senolytic drug program built around RLS-1496, a GPX4 modulator designed to selectively clear senescent cells. The senolytic field has yielded mixed clinical results so far, with the dasatinib-quercetin combination showing a signal in some studies but inconsistent results in others.
Rubedo’s strategy is to use AI to design a more selective and potent senolytic that avoids off-target toxicity, a limitation in earlier programs. Senescent-cell clearance remains one of the most biologically compelling longevity mechanisms we have, and a better-designed small molecule could meaningfully advance the field.
Broadening the Longevity Playbook
Not every compelling longevity company is built around reprogramming or AI. Two standout companies in this group are working with more established biology but applying it in completely new ways.
Retro Biosciences has taken a notable turn by combining its autophagy biology platform with a ChatGPT-assisted computational model that the company reports has improved reprogramming efficiency. Its Alzheimer’s program is built on autophagy activation rather than reprogramming. Researchers think that restoring the cell’s own clearance machinery, which degrades with age, may address the protein aggregate burden that drives neurodegeneration more directly than amyloid-targeted therapies alone.
This is an interesting hypothesis given the failures of upstream amyloid approaches, and autophagy enhancement has a growing translational evidence base.
Cambrian Bio takes the broadest portfolio approach of any company on this list, building a pipeline that includes a pan-AMPK activator, safer rapalog analogs, fibrosis programs, and ovarian function extension. This breadth reflects a strategy: the company is betting that multiple distinct biological drivers of aging (nutrient sensing, mTOR signaling, tissue fibrosis, reproductive aging) each represent independent therapeutic opportunities.
For clinicians, Cambrian’s portfolio is a map of where pharmacological longevity science currently sits, covering metabolic signaling, inflammation, tissue remodeling, and endocrine aging in a single company.
What to Watch For as a Clinician
The most important thing to understand about this group of companies is that scientific plausibility and clinical proof are not the same thing. Every mechanism described here (reprogramming, senolytics, autophagy activation, AI-guided transcription-factor targeting) has a credible biological rationale and, in most cases, supporting preclinical data.
What we do not yet have is robust human evidence that any of these approaches produces durable, meaningful functional benefit at acceptable safety profiles.
The companies doing the most serious work in the longevity field have accepted that the path to solving the “aging problem” runs through the same rigorous, disease-specific, outcome-defined clinical science that governs every other area of medicine.